Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,625,790
  • Shares Outstanding, K 140,883
  • Annual Sales, $ 102,430 K
  • Annual Income, $ -95,190 K
  • 60-Month Beta 2.28
  • Price/Sales 14.90
  • Price/Cash Flow N/A
  • Price/Book 3.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.41
  • Number of Estimates 5
  • High Estimate 2.02
  • Low Estimate -0.31
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +257.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.67 +18.30%
on 07/06/20
11.61 -1.46%
on 08/04/20
+1.81 (+18.80%)
since 07/02/20
3-Month
8.27 +38.33%
on 05/08/20
12.00 -4.67%
on 06/01/20
+3.06 (+36.52%)
since 05/04/20
52-Week
4.81 +137.84%
on 03/17/20
12.38 -7.59%
on 08/08/19
-0.01 (-0.09%)
since 08/02/19

Most Recent Stories

More News
Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer

Excision BioTherapeutics, a biotechnology company dedicated to curing viral infectious disease using CRISPR, today announced the appointment of TJ Cradick, PhD to the position of Chief Scientific Officer....

SGMO : 11.44 (-0.87%)
CRSP : 94.57 (+2.24%)
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

--- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales

SGMO : 11.44 (-0.87%)
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on...

SGMO : 11.44 (-0.87%)
Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy?

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SGMO : 11.44 (-0.87%)
Biogen (BIIB) Beats on Q2 Earnings, Raises EPS View, Stock Up

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock rises.

BIIB : 276.08 (-0.75%)
JNJ : 147.22 (-0.09%)
RHHBY : 43.8300 (-0.75%)
SGMO : 11.44 (-0.87%)
NASDAQ, S&P End 5-Day Winning Streaks

NASDAQ, S&P End 5-Day Winning Streaks

MSFT : 213.29 (-1.50%)
GPC : 91.19 (+0.36%)
SNBR : 46.36 (-0.77%)
STZ : 171.69 (-0.92%)
BBBY : 11.43 (+3.44%)
SOI : 7.30 (-1.22%)
THO : 116.51 (-3.50%)
SQQQ : 5.62 (-1.40%)
UNFI : 21.28 (+4.72%)
IAC : 133.85 (-0.13%)
RHP : 32.50 (+6.11%)
LVS : 43.73 (-0.61%)
HTHT : 35.73 (+2.29%)
RDS.A : 31.35 (+3.47%)
AYX : 176.28 (-0.73%)
MPC : 37.69 (-2.28%)
NEO : 38.81 (+0.54%)
STNE : 47.20 (-1.91%)
TJX : 53.28 (+2.68%)
TWTR : 36.35 (-0.11%)
XYL : 73.79 (+0.23%)
BLUE : 62.44 (-0.54%)
CRSP : 94.57 (+2.24%)
SGMO : 11.44 (-0.87%)
NTLA : 19.59 (+1.77%)
ACAD : 43.52 (+0.58%)
ALNY : 152.76 (+0.30%)
EDIT : 31.88 (+0.98%)
Sangamo Announces R&D Organization Changes

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.

SGMO : 11.44 (-0.87%)
Sangamo Therapeu Falls 2.76% on Heavy Volume: Watch For Potential Rebound

Sangamo Therapeu (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $10.40 to a high of $11.26. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of...

SGMO : 11.44 (-0.87%)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525,...

PFE : 38.39 (+0.10%)
SGMO : 11.44 (-0.87%)
Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?

Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.

SGMO : 11.44 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade SGMO with:

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

2nd Resistance Point 11.77
1st Resistance Point 11.61
Last Price 11.44
1st Support Level 11.28
2nd Support Level 11.11

See More

52-Week High 12.38
Last Price 11.44
Fibonacci 61.8% 9.49
Fibonacci 50% 8.60
Fibonacci 38.2% 7.70
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar